Business
Result of 2025 Annual General Meeting
Result of 2025 Annual General Meeting.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n\n\n\n\nFor immediate release\n\n\n30 June 2025\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nResult of 2025 Annual General Meeting\n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed.\n \nDetails of the voting will be available on the Company's website in due course.\n \n \nFor further information:\n \n\n\n\n\nANGLE plc\n\n\n+44 (0) 1483 343434\n\n\n\n\nAndrew Newland, Chief Executive\nIan Griffiths, Finance Director\n\n\n \n \n\n\n\n\n \nBerenberg (NOMAD and Broker)\nToby Flaux, Ciaran Walsh, Milo Bonser\n\n\n \n+44 (0) 20 3207 7800\n\n\n\n\n \nFTI Consulting\nSimon Conway, Ciara Martin\nMatthew Ventimiglia (US)\n\n\n \n \n+44 (0) 203 727 1000\n+1 (212) 850 5624\n\n\n\n\n \n \nNotes for editors\n \nAbout ANGLE plc\n \nANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.\n \nANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.\n \nOver 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com\n \n\n","length":5612,"tagName":"div"}]